Key Takeaways
Enzyme-instructed self-assembly (EISA) enables therapeutic nanostructures to form directly inside the body in response to disease-associated enzymatic signals.
By linking supramolecular chemistry with enzymatic activation, researchers can design precursor molecules that assemble selectively within specific biological environments.
Early studies have shown that enzyme-triggered peptide assemblies can form nanofibers, hydrogels, and intracellular structures capable of influencing cellular behavior.
Emerging research is integrating EISA with immunotherapy and combination cancer treatments, demonstrating how enzyme-triggered assembly can interact with complex biological pathways.
Although still largely in the research phase, EISA represents a step toward programmable therapeutic systems that respond dynamically to biological signals rather than relying on pre-formed delivery vehicles.
A Different Way to Construct a Therapeutic System
Most modern drug delivery technologies are designed and assembled before they ever reach the patient. Liposomes, polymer nanoparticles, viral vectors, and other delivery systems are manufactured as finished structures during formulation and then administered with the expectation that they will navigate the body’s complex biological environment while carrying their therapeutic payloads to the appropriate tissues. Over the past several decades, advances in nanotechnology and biomaterials science have produced increasingly sophisticated versions of these delivery vehicles, each engineered to improve stability, targeting, or pharmacokinetics. However, despite these innovations, the underlying model remains largely the same: the therapeutic system is built outside the body and delivered as a complete construct.
A growing area of chemical biology is beginning to explore a fundamentally different possibility. Instead of constructing complex therapeutic architectures during manufacturing, researchers are designing molecular components that assemble into functional structures only after they enter the body. In these systems, relatively simple precursor molecules circulate in an inactive or non-assembled form until they encounter specific biological signals that trigger structural transformation.
One of the most intriguing examples of this approach is enzyme-instructed self-assembly (EISA). In EISA systems, enzymatic reactions convert a soluble precursor molecule into a form capable of self-assembly through supramolecular interactions. Once activated, these molecules can organize into nanoscale structures, such as fibers, networks, or hydrogels directly within biological environments.1
The key feature that distinguishes this strategy from conventional nanomedicine lies in the role of enzymes as triggers for structural formation. Enzymes are not distributed uniformly throughout the body. Their expression levels vary among tissues and often change in response to disease processes, such as cancer or inflammation. By designing molecular precursors that respond to these enzymatic signals, researchers can create systems that assemble selectively where the relevant enzymes are active.2
This coupling of enzymatic activation with supramolecular assembly introduces a new conceptual framework for therapeutic design. Rather than delivering a fully formed nanomaterial, the therapeutic system can be programmed to build itself in situ, guided by the biological conditions present within specific tissues. In this sense, the disease environment becomes part of the construction process, helping determine where and when the therapeutic architecture emerges.
Enzymatic Triggers and Supramolecular Assembly
Self-assembly describes the spontaneous organization of molecules into ordered structures through non-covalent interactions such as hydrogen bonding, hydrophobic interactions, π–π stacking, and electrostatic forces. In biological systems, these interactions drive the formation of many natural structures, from lipid bilayers to cytoskeletal filaments. Supramolecular chemists have long sought to harness similar principles to construct functional materials from relatively simple molecular building blocks.
EISA integrates this supramolecular behavior with enzymatic chemistry. Rather than relying solely on the intrinsic properties of a molecule to initiate assembly, EISA systems incorporate a biochemical trigger. A precursor molecule is designed to remain soluble and non-assembling until it undergoes a specific enzymatic transformation. Once that transformation occurs, the molecule acquires structural features that promote intermolecular interactions and drive assembly into higher-order architectures.
In practice, the sequence of events is straightforward. A precursor molecule enters a biological environment in a form that does not readily assemble. When it encounters a particular enzyme, a chemical modification occurs. That modification produces an assembling molecule capable of organizing into supramolecular structures such as nanofibers or hydrogels. Through this sequence, enzymatic activity functions as the switch that initiates the assembly process.1
The use of enzymatic triggers introduces an important dimension of control. Enzymes exhibit highly specific substrate recognition, and their expression varies across tissues, developmental stages, and disease states. As a result, enzymatic reactions can provide both spatial and temporal regulation of supramolecular assembly. This mechanism allows nanostructures to form selectively in regions where the activating enzyme is present, enabling localized formation of supramolecular materials within biological environments.2
This feature is particularly relevant in disease contexts. Tumors, inflamed tissues, and other pathological environments often exhibit altered enzyme activity. By designing precursors that respond to these enzymatic signatures, researchers can exploit disease-associated biochemical conditions to initiate assembly at the site of pathology.
Among the molecular platforms explored for EISA, peptides have emerged as one of the most versatile. Peptide sequences can be engineered with precise control over charge, hydrophobicity, and intermolecular interaction motifs, all of which influence their ability to assemble into supramolecular structures. Protease-mediated transformations, for example, can convert peptide precursors into assembling forms that organize into nanofibers or other biomaterials with potential biomedical applications.1
Through these strategies, EISA demonstrates how enzymatic chemistry and supramolecular design can be combined to create responsive molecular systems. Instead of constructing complex nanomaterials during manufacturing, researchers can encode assembly instructions directly into molecular precursors that respond to biological signals.
Early Demonstrations of Enzyme-Triggered Assembly
The concept of EISA emerged from early experiments showing that enzymatic reactions could be used to initiate supramolecular assembly within biological environments. These studies demonstrated that relatively simple molecular precursors could be converted by enzymes into assembling species that organize into nanoscale structures under physiological conditions.
One influential demonstration involved peptide derivatives designed to undergo enzymatic dephosphorylation. In this system, the precursor molecule contained a phosphate group that maintained the peptide in a soluble, non-assembling state. When the phosphate group was removed by an enzyme, the resulting molecule acquired the ability to self-assemble through intermolecular interactions. The reaction triggered the formation of supramolecular nanofibers that could further organize into hydrogel-like networks.1
The significance of this work lay not only in the structures produced but also in where they formed. Because the assembly process depended on enzymatic activity, the nanofibers emerged within the biological environment where the reaction occurred. The resulting supramolecular materials were investigated for potential applications including intracellular imaging and intratumoral chemotherapy, illustrating how enzymatic activation could generate functional biomaterials directly inside tissues.
These early experiments established a key mechanistic insight that continues to shape the field: a small chemical modification introduced by an enzyme can alter the balance of intermolecular forces sufficiently to drive supramolecular assembly. In other words, the enzymatic step does not build the final structure itself. Instead, it converts the precursor into a molecule whose physical chemistry favors spontaneous organization.
Subsequent studies expanded on this concept by exploring different molecular designs and biological triggers. One notable example involved the use of small ᴅ-peptide precursors capable of undergoing enzyme-instructed self-assembly inside cells. In this system, enzymatic reactions initiated the formation of intracellular supramolecular structures that disrupted cellular processes and selectively induced cancer cell death.3
The results suggested that EISA could function not only as a materials strategy but also as a therapeutic mechanism. Rather than delivering a conventional cytotoxic drug, the system produced supramolecular structures that altered the cellular environment after enzymatic activation.
These early demonstrations provided proof that enzymatic reactions could serve as reliable triggers for supramolecular assembly in complex biological environments. They also revealed the broader potential of the approach: by linking molecular assembly to enzyme activity, it becomes possible to create therapeutic structures whose formation is guided by the biochemical conditions present in diseased tissues.
Intracellular Peptide Assemblies and New Therapeutic Mechanisms
As the EISA field matured, researchers began exploring how the same principles could be applied inside cells rather than only in extracellular environments. Early demonstrations had focused largely on the formation of supramolecular materials, such as nanofibers or hydrogels, in the surrounding tissue environment. More recent work has shown that enzymatic reactions occurring within cells can also initiate the assembly of peptide-based nanostructures.
In these systems, molecular precursors are designed to enter cells in a soluble form that does not readily assemble. Once inside the cell, enzymatic activity converts the precursor into a molecule capable of forming supramolecular structures. The resulting assemblies can organize into nanoscale fibers, networks, or other ordered architectures within the intracellular environment. Enzymatic transformations can drive the formation of these structures directly within living cells, enabling new approaches to modulating cellular behavior.
The shift toward intracellular assembly expands the potential scope of EISA considerably. Cells contain highly complex biochemical environments, with dense networks of proteins, organelles, and signaling pathways. When supramolecular structures form within this environment, they can interact with these systems in ways that influence biological function. These structures can affect cellular processes, such as signaling pathways, molecular trafficking, and metabolic activity.2
Because the assembly process is triggered by enzymatic reactions, the formation of these intracellular structures remains linked to specific biochemical signals. Enzyme expression patterns vary widely across cell types and disease states, creating opportunities to design precursors that respond selectively to the enzymatic profiles associated with particular pathological conditions.
This ability to initiate supramolecular assembly inside cells introduces a different perspective on therapeutic design. Instead of relying solely on drug molecules that bind to individual molecular targets, EISA systems can create nanoscale architectures that reshape aspects of the intracellular environment itself. By influencing the physical organization of molecules within cells, these assemblies may alter biological processes in ways that conventional small molecules cannot easily achieve.
As a result, EISA is increasingly viewed not only as a drug delivery strategy but also as a broader platform for engineering biological responses through the controlled formation of supramolecular structures within living systems.
Expanding the Concept: EISA in Immunotherapy and Combination Therapies
As the basic principles of EISA became better understood, researchers began exploring how the approach might be integrated with emerging therapeutic strategies, particularly in oncology. Rather than using enzyme-triggered assembly only to generate biomaterials or localized drug depots, newer studies have investigated how supramolecular assembly could interact with complex biological pathways involved in immune regulation and cancer therapy.
One line of work has examined systems in which molecular components assemble directly within the tumor microenvironment to influence immune signaling. In one example, researchers designed a system in which peptide components assemble in situ with antibodies to form supramolecular complexes capable of interfering with immune checkpoint pathways. In experimental models of breast and pancreatic cancer, this strategy enhanced macrophage-mediated phagocytosis of tumor cells, illustrating how EISA can be integrated with immunotherapy mechanisms.4
This approach reflects a broader trend toward combining supramolecular assembly with immune modulation. Because the tumor microenvironment often exhibits distinctive enzymatic activity, it provides a biochemical context in which enzyme-triggered assembly can be selectively activated. By designing molecular precursors that respond to these enzymatic signals, researchers can generate therapeutic architectures that emerge directly within tumor tissues and interact with local immune processes.
Other studies have explored combination strategies in which enzyme-triggered self-assembly operates alongside more conventional anticancer therapies. One example involves dual enzyme-triggered peptide systems designed to coordinate supramolecular assembly with chemotherapeutic activity. In these designs, multiple enzymatic reactions participate in activating the assembly process, leading to the formation of nanostructures that enhance immunogenic cancer cell death and improve the therapeutic response to chemotherapy.5
These developments highlight how EISA can function as more than a localized drug delivery mechanism. By integrating enzyme-responsive molecular design with immunotherapy or chemotherapeutic strategies, researchers are beginning to construct therapeutic systems capable of engaging multiple biological processes simultaneously.
As the complexity of these designs increases, EISA is evolving from a method for generating supramolecular materials in biological environments into a broader platform for building multifunctional therapeutic architectures. In these systems, enzymatic activity serves not only as the trigger for molecular assembly but also as the entry point for coordinating multiple therapeutic mechanisms within the same molecular framework.
Advantages and Design Potential of Enzyme-Triggered Assembly
The design logic behind EISA differs in several important ways from conventional drug delivery systems. Instead of relying on pre-formed nanoparticles or biomaterials constructed during manufacturing, EISA begins with relatively simple molecular precursors whose behavior changes in response to enzymatic signals within biological environments.
One of the most significant implications of this design strategy is the possibility of localized activation. Because the assembly process depends on enzymatic reactions, supramolecular structures can form selectively in tissues where the relevant enzymes are present. Enzyme expression often varies substantially across different physiological and pathological environments, including tumors and sites of inflammation. By exploiting these biochemical differences, EISA systems can potentially generate therapeutic structures preferentially within diseased tissues.
Enzymatic triggers also introduce a level of spatiotemporal control that is difficult to achieve with many traditional delivery systems. The timing and location of supramolecular assembly become linked to the presence and activity of specific enzymes, allowing molecular structures to form only after the precursor encounters the appropriate biological signal. This property enables researchers to design systems that remain relatively inactive during circulation and undergo structural transformation only after reaching target tissues.
Another distinguishing feature of EISA lies in the relative simplicity of its molecular building blocks. Conventional nanomedicine platforms often require complex fabrication processes to construct stable nanoparticles or polymer carriers before administration. In contrast, EISA strategies can rely on small precursor molecules that assemble into larger supramolecular architectures only after enzymatic activation. The structural complexity of the final therapeutic material therefore emerges from interactions among molecules within the biological environment rather than from manufacturing steps alone.1
These characteristics illustrate the broader design potential of enzyme-triggered assembly. By linking molecular structure formation to biochemical signals, EISA systems can function as responsive therapeutic platforms that adapt dynamically to the biological environments in which they operate.
Translational Challenges and Future Research
Despite the growing body of experimental work, the field remains largely at the research stage. Most studies to date have focused on establishing proof-of-concept systems and exploring the fundamental chemistry that governs enzyme-triggered assembly. Translating these findings into clinically viable therapeutics presents several significant scientific and engineering challenges.
One important area of ongoing research involves understanding how supramolecular assemblies behave within complex biological environments. While many EISA systems assemble predictably under controlled laboratory conditions, biological tissues contain dense mixtures of proteins, membranes, and other biomolecules that can influence molecular interactions. The mechanisms governing assembly, stability, and disassembly in living systems remain an active area of investigation.
Another challenge lies in controlling the pharmacokinetics and biodistribution of precursor molecules. Because EISA relies on precursors that assemble only after enzymatic activation, their ability to reach the intended biological environment in sufficient concentrations is critical. Factors like precursor stability, cellular uptake, and enzymatic specificity all influence whether the assembly process occurs in the desired location.
Designing systems with predictable and reproducible behavior also remains an important objective. Supramolecular structures arise from the collective interactions of many molecules, which can make their formation sensitive to environmental conditions. Achieving reliable control over these assembly processes in vivo will be essential for therapeutic translation.
Addressing these challenges will require continued collaboration across multiple scientific disciplines. Advances in peptide chemistry, supramolecular materials science, enzymology, and biomedical engineering all contribute to improving the design and performance of EISA systems. As these fields converge, researchers are gradually building the mechanistic understanding needed to move enzyme-triggered assembly from laboratory demonstrations toward practical biomedical applications.
Outlook: Toward Programmable Therapeutic Systems
EISA reflects a broader shift in biotechnology toward therapeutic systems that respond dynamically to biological signals. Traditional drug development has focused primarily on designing molecules or delivery vehicles whose structure and function are fixed before administration. Once delivered, these systems interact with biological targets but generally do not change their fundamental architecture.
EISA introduces a different design logic. Instead of delivering a fully constructed therapeutic structure, researchers can deliver molecular precursors whose behavior is governed by biochemical cues encountered inside the body. Enzymatic reactions act as triggers that convert these precursors into assembling molecules, allowing supramolecular structures to form only when the appropriate biological conditions are present.
This strategy opens the possibility of therapeutic systems that operate more like programmable materials than conventional drugs. Molecular components can be engineered to respond to specific enzymatic signatures associated with discrete tissues or disease states. When those signals are encountered, the molecules assemble into functional architectures that carry out the intended therapeutic activity.
If these approaches can be translated into clinically viable therapies, they could enable new strategies for localized treatment and responsive drug delivery. Instead of relying entirely on external manufacturing to produce complex nanomaterials, researchers may increasingly design therapeutic systems in which biological environments themselves guide the construction of functional structures.
In this emerging paradigm, therapeutic architectures are not only delivered to the body. They are assembled within it, shaped by the biochemical signals that define health and disease.
References
1. Gao, Jie, Jie Zhan, and Zhimou Yang. “Enzyme-Instructed Self-Assembly (EISA) and Hydrogelation of Peptides.” Advanced Materials. 24 Apr. 2019.
2. Kim, Beom Jin and Bing Xu. “Enzyme-Instructed Self-Assembly for Cancer Therapy and Imaging.” Bioconjug. Chem. 31: 492–500 (2021).
3. Zhou, Jie, et al. “Enzyme-Instructed Self-Assembly of Small ᴅ-Peptides as a Multiple-Step Process for Selectively Killing Cancer Cells." Journal of the American Chemical Society. 11 Mar. 2016.
4. Zhang, Weiqi, et al. “An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses.” Nature Communications. 15: 5670 (2024).
5. Wang, Yuhan, et al. “Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma.” Bioactive Materials. 31: 449–562 (2024).
